<DOC>
	<DOCNO>NCT00311623</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , sirolimus , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This clinical trial study best dose sirolimus see well work surgery treat patient advance localized prostate cancer .</brief_summary>
	<brief_title>Sirolimus Before Surgery Treating Patients With Advanced Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pharmacodynamically optimal dose ( POD ) continuous daily oral sirolimus ( rapamycin ) patient advance localized prostate cancer give prior radical prostatectomy , measure tumor S6 kinase inhibition immunohistochemistry ( IHC ) . - Determine proportion men downstream target inhibition prostate tumor tissue POD use paired tumor biopsy rapamycin administration . - Correlate tumor pharmacodynamic ( PD ) efficacy surrogate marker tumor PD efficacy , peripheral blood mononuclear cell ( PBMC ) S6 kinase activity inhibition . Secondary - Characterize serum prostate tissue pharmacokinetics daily oral rapamycin 2 dose level . - Determine relationship PD target inhibition S6 kinase activity pretreatment Akt activity PTEN loss IHC prostate cancer . - Describe relationship PD inhibition mTOR inhibitor rapamycin pretreatment prostate biopsy Gleason sum , Ki-67 index proliferation , Akt activity , p27 IHC , PTEN . - Correlate PD efficacy measure downstream S6 kinase activity inhibition marker increase apoptosis ( activated caspase 3 ) reduction marker proliferation ( change Ki-67 ) prostate tumor specimen . - Quantify characterize toxicity daily continuous rapamycin 2 dose level generally healthy men prostate cancer prior surgery . - Evaluate activity rapamycin prostate cancer measure prostate specific antigen response prior surgery . OUTLINE : This multicenter , dose-escalation study . Patients receive oral sirolimus ( rapamycin ) daily day 1-14 absence unacceptable toxicity . Cohorts 12-21 patient receive escalate dos rapamycin pharmacodynamically optimal dose determine . Patients undergo radical prostatectomy day 15 . Patients undergo blood collection tumor biopsy periodically study pharmacologic correlative biomarker study . After completion study treatment , patient follow 30 90 day . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically determine adenocarcinoma prostate Stage T1cT3b disease No evidence disease spread beyond prostate seminal vesicle No metastatic prostate cancer , include bone , visceral , brain , lymph node metastasis Tumor Gleason score sum 710 ( 4+3 3+4 allow ) tumor involve least 2 discrete core biopsy section Scheduled undergo radical prostatectomy No subtypes prostate cancer , include follow : Sarcoma Neuroendocrine tumor Small cell cancer Ductal cancer Lymphoma PATIENT CHARACTERISTICS : ECOG performance status 01 WBC &gt; 3,500/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 9 g/dL Creatinine &lt; 2.0 mg/dL Bilirubin &lt; 2 mg/dL ALT AST &lt; 2 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 2 time ULN Triglycerides total cholesterol &lt; 2 time ULN No history allergy sirolimus ( rapamycin ) derivatives No uncontrolled medical condition would increase risk limit compliance study requirement , include follow : Immunodeficiency Gastrointestinal disease would limit ability swallow , take oral medication , absorb No active infection No concurrent malignancy PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy , biologic therapy , radiotherapy , immunotherapy prostate cancer No concurrent chronic treatment immunosuppressant medication interfere metabolism sirolimus ( rapamycin ) No concurrent medication agent would interfere metabolism excretion rapamycin derivative , include follow : Phenytoin Carbamazepine Cyclosporine Clarithromycin Clotrimazole Erythromycin Amiodarone Protease inhibitor use treat HIV infection Cisapride Grapefruit juice Diltiazem Tacrolimus Hypericum perforatum ( St. John 's wort ) Barbiturates Rifampin Phenobarbital Rifabutin Efavirenz Nevirapine At least 7 day since prior herbal medicine medication , include follow : Hydrastis canadensis ( goldenseal ) Uncaria tomentosa ( cat 's claw ) Echinacea angustifolia root Trifolium pretense ( wild cherry ) Chamomile Glycyrrhiza glabra ( licorice ) Dillapiol Naringenin Norfloxacin Atorvastatin Pravastatin Cimetidine Fluconazole</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>